EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mimicry of Tumour-Associated Carbohydrates: Is It a Promising Option for Cancer Treatment?

Valeria Inés Segatori, Gretel Magalí Ferreira, Selene Rojo, Aylen Camila Nogueira, Jeremías Omar Castillo, Cynthia Antonella Gulino, Mariano Rolando Gabri

Immuno · 23.03.2023 · 3 (2) · 122-147

DOI: 10.3390/immuno3020009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immuno, online erschienen am 23.03.2023. Verfasst von Valeria Inés Segatori und 6 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 209 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Nacional de Quilmes, Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación, Argentina.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Modulation of the immune system has been demonstrated as a powerful approach to treating cancer. Immunotherapies are generally classified as active or passive according to their ability to trigger the immune system. During the last decades, information regarding the relevance of aberrant glycosylation as a major player in tumour biology encouraged expectations for the development of new therapeutic strategies directed at glycans. Several tumour-associated carbohydrate antigens (TACAs) have been identified and validated as suitable immunotherapeutic targets, leading to promising therapeutic developments. It is known that TACAs are poorly immunogenic since they are unable to trigger a proper immune response. Given that they are not presented by major histocompatibility complex (MHC) molecules and that they induce immune tolerance, the development of active immunotherapeutic strategies against TACAs is a real challenge. However, antitumor strategies based on mimetics of TACAs have been developed and show promising results. Active immunotherapies based on TACAs mimicry can currently be grouped into strategies based on the use of mimetic peptides and anti-idiotype (Id) antibodies. In this review, we discussed the scientific basis on which these strategies are based and the available therapeutic options that have shown the best results in preclinical studies and in clinical practice.

Förderung

  • Universidad Nacional de Quilmes
  • Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación, Argentina

Zitieren

APA

Segatori, V. I., Ferreira, G. M., Rojo, S., Nogueira, A. C., Castillo, J. O., Gulino, C. A., & Gabri, M. R. (2023). Mimicry of Tumour-Associated Carbohydrates: Is It a Promising Option for Cancer Treatment?. Immuno, 3(2), 122-147. https://doi.org/10.3390/immuno3020009

Vancouver

Segatori VI, Ferreira GM, Rojo S, Nogueira AC, Castillo JO, Gulino CA, et al. Mimicry of Tumour-Associated Carbohydrates: Is It a Promising Option for Cancer Treatment?. Immuno. 2023;3(2):122-147. doi:10.3390/immuno3020009

BibTeX
@article{Segatori2023,
  author = {Segatori, Valeria Inés and Ferreira, Gretel Magalí and Rojo, Selene and Nogueira, Aylen Camila and Castillo, Jeremías Omar and Gulino, Cynthia Antonella and Gabri, Mariano Rolando},
  title = {Mimicry of Tumour-Associated Carbohydrates: Is It a Promising Option for Cancer Treatment?},
  journal = {Immuno},
  year = {2023},
  volume = {3},
  number = {2},
  pages = {122--147},
  doi = {10.3390/immuno3020009}
}
Kostenlos starten →